Market Update: Eli Lilly & Company (NYSE:LLY) – Panel recommends Merck & Co continue cholesterol drug study

[Reuters] – Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug, anacetrapib. The recommendation comes a month after Eli Lilly & . . . → Read More: Market Update: Eli Lilly & Company (NYSE:LLY) – Panel recommends Merck & Co continue cholesterol drug study Similar Articles: Market Update (NYSE:LLY): U.S. federal agencies investigate Merck, Lilly drug pricing Stock Update (NYSE:LLY): Lilly continues test of HDL cholesterol drug, on panel’s advice Market Update: Eli Lilly & Company (NYSE:LLY) – FDA asks panel to weigh benefit, risk of Lilly lung cancer drug